US Pharma MarketingFrench gene therapy biotech gets €33M to follow Krystal
Cyllene Therapeutics raised €33 million in a Series C and rebranded from EG 427 as it starts a potentially registrational Phase 2/3 next year in neurogenic detrusor overactivity. Topic Hubs AI drug discovery: News, analysis and interviews Antibody-drug conjugates: The next wave of targeted cancer drugs Biopharma M&A and dealmaking: Who’s buying and why Biopharma people moves: CEO changes, executive hires, board positions Biotech IPOs: Tracking the market for new public offerings Biotech venture funding: Who’s raising and where the money is going Cell and gene therapy manufacturing: Scaling the next frontier China biotech: Licensing deals and the Biosecure Act…
A small French-US biotech has gathered more funds to see if it can follow in the footsteps of Krystal Biotech in the HSV-based gene therapy field, but in a different therapeutic area.
Cyllene Therapeutics raised ...
Source: Endpoints News